(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2(Date:9/3/2008)...ldren Studied. Wrong,Conclusions Reached., NIXA, ...for Disease,Control and Prevention (CDC) study rel...R vaccine and autism. The National Autism Associat...he growing public concern over a,vaccine-autism co...esign,and methodology., For years, parents have c...
(Date:9/3/2008)...ically infected Hepatitis C,patients strongly conf...008, - Study is the first to show a statisticall...t of therapeutic Hepatitis C vaccination, - Data...ond generation, vaccine formulated with Intercell... activation, VIENNA, Austria, S...
(Date:9/3/2008)...-- Panacea Pharmaceuticals,Inc. today announced t...ng,antibodies against human aspartyl (asparaginyl)...er biomarker and therapeutic target. These antibod...chusetts Institute of,Technology (MIT) and Panacea...r development of human cancer diagnostics and ther...
(Date:9/3/2008)...o Launch Progress and Adlea ...e Call Today at 11:30 am ET, SOUTH SAN FRANCISCO,...,Inc. (Nasdaq: ANSV ) announced today that the c...mercial and late-stage product development to,acce...l pain management,company. The company also provid...
Breaking Medicine Technology:CDC Misses Target With Flawed MMR/Autism Study 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 1American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 2American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 3American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 4American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 5American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 6American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 7American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 8American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 9American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 10American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 11American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 12American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 13AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 1AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 2AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 3AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 4BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP 1 Gene in Multiple Cancer Types 668 1BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP 1 Gene in Multiple Cancer Types 668 2Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization 665 1Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization 665 2Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization 665 3...y shows paroxetine produced no significant drug in... 2007 /PRNewswire/ -- After administration of,pali...ls of the,drug were not affected when given with a...ented today at the 160th Annual Meeting,of the Ame...tive,serotonin reuptake inhibitor (SSRI), is an an...
...AGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ --...ntly completed animal,study, a DNA vaccine formula...vant and delivered by needle-free injection,yielde...unformulated DNA vaccine delivered by needle and s...n following injection of,unformulated vaccine yiel...
Other Medicine Technology:Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 2Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 3Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 4Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 5Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 6Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 2Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 3Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 4The CRW system is the premier stereotactic system. The CRW system can be configured as a basic CT-only system, a CT/MR scanner-dependent system, or a high-level CT/MR scanner-independent system with
Table-mounted, retraction for radiolucent anterior spine procedures. Fully-adjustable for any approach and any patient. Combine with our radiolucent blade kit for optimal visibility.
Corlok Allografts are unique corticocancellous allografts comprised of an anterior cortical face and a unique Dovetail geometry permitting a precise interlocking fit with adjacent vertebrae. Corlok A
Solid cortical spacers with a natural anatomic fibular shape.
Medicine Products: